Philippe Reix

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

Félix Ratjen, Christopher Hug, Gautham Marigowda et al. · The Lancet Respiratory Medicine · 2017 · 295 citations

Medicine, Pediatrics, Pharmacotherapy +12

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for <i>F508del</i> and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study

Marcus Mall, Rossa Brugha, Silvia Gärtner et al. · American Journal of Respiratory and Critical Care Medicine · 2022 · 140 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +15

Severe Pulmonary Fibrosis as the First Manifestation of Interferonopathy (TMEM173 Mutation)

Cécile Picard, Guillaume Thouvenin, Caroline Kannengiesser et al. · CHEST Journal · 2016 · 135 citations · Full text

Medicine, Immunology, Pathology +16

Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis

Pierre‐Régis Burgel, À. Munck, I. Durieu et al. · American Journal of Respiratory and Critical Care Medicine · 2019 · 132 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

New insights into pediatric idiopathic pulmonary hemosiderosis: the French RespiRare® cohort

Jessica Taytard, Nadia Nathan, J. de Blic et al. · Orphanet Journal of Rare Diseases · 2013 · 127 citations · Full text

Medicine, Clinical Sciences, Pediatrics +7